Back to top
more

Mallinckrodt public limited company (MNK)

(Delayed Data from NYSE)

$16.14 USD

16.14
1,972,598

+0.44 (2.80%)

Updated May 3, 2019 04:02 PM ET

After-Market: $16.14 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Mallinckrodt (MNK) Q2 Earnings Beat Estimates

Mallinckrodt (MNK) delivered earnings and revenue surprises of 20.48% and -0.05%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Mallinckrodt (MNK) Reports Next Week: Wall Street Expects Earnings Growth

Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel

Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.

Will Mallinckrodt (MNK) Beat Estimates Again in Its Next Earnings Report?

Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Mallinckrodt (MNK) Outpaces Stock Market Gains: What You Should Know

Mallinckrodt (MNK) closed the most recent trading day at $9.18, moving +1.89% from the previous trading session.

Mallinckrodt Presents Encouraging Data on Acthar Gel for RA

Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.

Mallinckrodt Down After Agreement with DOJ for Litigation

Mallinckrodt (MNK) expects to pay $15.4 million to DOJ in relation with the Questcor litigation.

Why Is Mallinckrodt (MNK) Down 47.4% Since Last Earnings Report?

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cara Shares Up on Positive Phase III Data for Itchiness Drug

Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.

Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down

Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.

Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS

Mallinckrodt (MNK) declines after filing suit against HHS and CMS for the protection of Medicaid patient access to Acthar.

Mallinckrodt Ends Enrollment in Phase III for Terlipressin

Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.

Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View

Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.

Mallinckrodt (MNK) Surpasses Q1 Earnings and Revenue Estimates

Mallinckrodt (MNK) delivered earnings and revenue surprises of 12.14% and 2.47%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings?

Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.

Mallinckrodt (MNK) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Mallinckrodt (MNK) closed at $15.29, marking a -1.1% move from the previous day.

Mallinckrodt (MNK) Earnings Expected to Grow: Should You Buy?

Mallinckrodt (MNK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Bausch Health (BHC) Q1 Earnings?

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.

5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates

So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.

MNK or AMPH: Which Is the Better Value Stock Right Now?

MNK vs. AMPH: Which Stock Is the Better Value Option?

Mallinckrodt (MNK) Stock Sinks As Market Gains: What You Should Know

Mallinckrodt (MNK) closed the most recent trading day at $21.66, moving -0.18% from the previous trading session.

Will Mallinckrodt (MNK) Beat Estimates Again in Its Next Earnings Report?

Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs

Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.

Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study

Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.

Zacks Value Trader Highlights: G-III Apparel, General Motors, Legg Mason, Mallinckrodt and United Natural Foods

Zacks Value Trader Highlights: G-III Apparel, General Motors, Legg Mason, Mallinckrodt and United Natural Foods